Is Mahamaya Lifesciences the Best Stock in Its Sector? A Look at the Numbers

Is Mahamaya Lifesciences the best stock in its sector? The stock trades on the BSE at Rs 173 as of 22 October 2026, within its 52-week range of Rs 111.00 to Rs 205.05. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Mahamaya Lifesciences

Mahamaya Lifesciences Ltd manufactures, registers and exports crop protection products and bioproducts, and company information says it was incorporated in 2002. Company information says it makes pesticide formulations and supplies bulk products to Indian agrochemical companies and multinationals, importing researched molecules, securing registrations with the Central Insecticides Board and developing them into technical grade and value added formulations. At a market capitalisation of Rs 404 Cr, it is tracked as part of the Crop Protection Formulations sector on Univest.

Is Mahamaya Lifesciences the Best Stock in Its Sector?

Mahamaya Lifesciences' case in the sector rests on return quality rather than cheap valuation, since the stock trades at a premium to its Industry P/E. Mahamaya Lifesciences' 24.44x P/E is below Sumitomo Chemical India at 34.78x, though above the 23.29x Industry P/E and Dhanuka Agritech at 14.34x, while its 13.55% ROE is lower than Dhanuka Agritech at 17.08% and Sumitomo Chemical India at 16.02%, and its debt to equity ratio of 0.74 is above Dhanuka Agritech at 0.02 and Sumitomo Chemical India at 0.02.

Metric	Mahamaya Lifesciences
CMP (BSE)	Rs 172.55
52-Week High / Low	Rs 205.05 / Rs 111.00
Market Cap	Rs 404 Cr
P/E (TTM) vs Industry P/E	24.44x vs 23.29x
P/B	3.31
ROE	13.55%
EPS (TTM)	Rs 7.06
Dividend Yield	0.00%
Debt to Equity	0.74

Compare Mahamaya Lifesciences Against Other Crop Protection Formulations Sector Stocks

How Mahamaya Lifesciences Compares Against Its Crop Protection Formulations Sector Peers

The table below sets Mahamaya Lifesciences against 2 other Crop Protection Formulations sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Mahamaya Lifesciences	404	24.44	13.55%	0.74
Dhanuka Agritech	3,845	14.34	17.08%	0.02
Sumitomo Chemical India	20,153	34.78	16.02%	0.02
Peer average (2 companies)	-	24.56	16.55%	0.02

Measured against the peer averages, Mahamaya Lifesciences' P/E is almost level with the 24.56x average, and its ROE is 3.00 percentage points below the 16.55% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.

What Makes Mahamaya Lifesciences Worth Watching in Crop Protection Formulations

• Scale: At Rs 404 Cr, its market capitalisation is smaller than Dhanuka Agritech (Rs 3,845 Cr) and Sumitomo Chemical India (Rs 20,153 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
• Sector drivers: Volumes supplied to agrochemical companies, product registrations it holds and raw material costs drive revenue and margins.
• Key risk: Farm chemical demand follows monsoon and crop cycles, and sales to a few large customers can be uneven. Regulation of pesticide molecules may change what it can sell.

Mahamaya Lifesciences Valuation: Is It Justified?

At a P/B ratio of 3.31, the market pays about Rs 3.31 for every rupee of book value, and the EPS (TTM) of Rs 7.06 is the earnings base behind the P/E. The stock trades about 16 percent below its 52-week high and about 55 percent above its 52-week low. The company does not currently show a dividend yield, so returns for shareholders depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Mahamaya Lifesciences and other Crop Protection Formulations sector stocks.

How to Track Mahamaya Lifesciences Before You Invest

Before deciding whether Mahamaya Lifesciences deserves its label as the best stock in its sector for your own portfolio, compare it directly against Crop Protection Formulations sector peers using the steps below.

1. Open the Univest Screener and search for Mahamaya Lifesciences to view live price, valuation ratios, and peer comparisons within the Crop Protection Formulations sector.
2. Compare its P/E, P/B, and ROE against other Crop Protection Formulations sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Mahamaya Lifesciences gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Crop Protection Formulations depends on how much weight you give each of them and on how the business executes from here. Because the stock trades above its sector benchmark, execution matters more than usual if the current valuation is to hold. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Mahamaya Lifesciences the best stock in its sector?

Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Mahamaya Lifesciences has a 13.55% ROE and trades at 24.44x P/E against a 23.29x Industry P/E. Against the 2 peers compared in this article, its ROE is below the 16.55% peer average and its P/E is below the 24.56x peer average. Its debt to equity ratio of 0.74 is above the 0.02 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.

What is the current share price of Mahamaya Lifesciences?

Ans. Mahamaya Lifesciences was trading at Rs 172.55 on the BSE as of 22 October 2026, and its 52-week range runs from Rs 111.00 to Rs 205.05. That leaves the share price 16 percent short of the 52-week high and 55 percent clear of the 52-week low. Its market capitalisation is Rs 404 Cr and its EPS (TTM) is Rs 7.06, which is the earnings figure behind the 24.44x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.

What sector does Mahamaya Lifesciences belong to?

Ans. Mahamaya Lifesciences is classified under the Crop Protection Formulations sector on Univest, and that group of listed companies is the reference point for the 23.29x Industry P/E used in this article. The 2 named peers compared here are Dhanuka Agritech and Sumitomo Chemical India, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Crop Protection Formulations sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.

How does Mahamaya Lifesciences compare to its sector peers on P/E?

Ans. Mahamaya Lifesciences' P/E of 24.44x is below the 24.56x average of the 2 named peers, with Dhanuka Agritech at 14.34x and Sumitomo Chemical India at 34.78x. It also sits above the 23.29x Industry P/E, which is the benchmark for the wider Crop Protection Formulations sector. A P/E that is below a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 3.31 gives one more view of how the market values its book value.

What is Mahamaya Lifesciences' return on equity?

Ans. Mahamaya Lifesciences reported a return on equity of 13.55%, which is below the 16.55% average of its named peers, with Dhanuka Agritech at 17.08% and Sumitomo Chemical India at 16.02%. ROE shows how much profit a company generates on every rupee of shareholders' equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.74 against a peer average of 0.02. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.

Should I invest in Mahamaya Lifesciences based on its sector position?

Ans. Sector position is only one input into an investment decision. Mahamaya Lifesciences has a 13.55% ROE and a 24.44x P/E, which make it worth researching further, and its dividend yield is 0.00%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.